Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Harvard Bioscience (HBIO) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Harvard Bioscience (HBIO) over the last 16 years, with Q3 2025 value amounting to -$1.3 million.

  • Harvard Bioscience's Non Operating Income rose 4914.02% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.3 million, marking a year-over-year increase of 5533.84%. This contributed to the annual value of -$5.5 million for FY2024, which is 2256.18% down from last year.
  • Latest data reveals that Harvard Bioscience reported Non Operating Income of -$1.3 million as of Q3 2025, which was up 4914.02% from -$1.4 million recorded in Q2 2025.
  • Harvard Bioscience's 5-year Non Operating Income high stood at $579000.0 for Q4 2024, and its period low was -$2.9 million during Q2 2023.
  • For the 5-year period, Harvard Bioscience's Non Operating Income averaged around -$960421.1, with its median value being -$690000.0 (2021).
  • Examining YoY changes over the last 5 years, Harvard Bioscience's Non Operating Income showed a top increase of 14180.51% in 2024 and a maximum decrease of 80539.08% in 2024.
  • Harvard Bioscience's Non Operating Income (Quarter) stood at -$568000.0 in 2021, then increased by 23.42% to -$435000.0 in 2022, then crashed by 218.39% to -$1.4 million in 2023, then skyrocketed by 141.81% to $579000.0 in 2024, then plummeted by 329.88% to -$1.3 million in 2025.
  • Its Non Operating Income was -$1.3 million in Q3 2025, compared to -$1.4 million in Q2 2025 and -$1.1 million in Q1 2025.